Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

199 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Vital Signs Screening Visit Mepolizumab HES NCT00086658 - Vital Signs Screening Visit

- 04/06/2017 - 1 Formulaire, 1 Groupe Item, 9 Eléments de données, 1 Langue
Groupe Item: VITAL SIGNS
Study part: Vital Signs Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

12-Lead ECG Screening Visit Mepolizumab HES NCT00086658 - 12-Lead ECG Screening Visit

- 04/06/2017 - 1 Formulaire, 1 Groupe Item, 3 Eléments de données, 1 Langue
Groupe Item: 12-Lead ECG
Study part: 12-Lead ECG Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

HES History or Prior HES Therapies Screening Visit Mepolizumab HES NCT00086658 - HES History or Prior HES Therapies Screening Visit

- 04/06/2017 - 1 Formulaire, 2 Groupes Item, 27 Eléments de données, 1 Langue
Groupes Item: DIAGNOSIS, Therapy HES
Study part: HES History or Prior HES Therapies Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

HES Related Medical Conditions Screening Visit Mepolizumab HES NCT00086658 - HES Related Medical Conditions Screening Visit

- 04/06/2017 - 1 Formulaire, 8 Groupes Item, 34 Eléments de données, 1 Langue
Groupes Item: Cardiac disorders, NERVOUS SYSTEM DISORDERS, Skin diseases, GASTROINTESTINAL DISORDERS, MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, EYE DISORDERS, RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, medical history Hypereosinophilic Syndrome
Study part: HES Related Medical Conditions Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Medical Conditions Screening Visit Mepolizumab HES NCT00086658 - Medical Conditions Screening Visit

- 04/06/2017 - 1 Formulaire, 1 Groupe Item, 23 Eléments de données, 1 Langue
Groupe Item: MEDICAL CONDITIONS
Study part: Medical Conditions Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Demographics Screening Visit Mepolizumab HES NCT00086658 - Demographics Screening Visit

- 04/06/2017 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 1 Langue
Groupe Item: Demography
Study part: Demographics Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Eligibility Criteria Worksheet Screening Visit Mepolizumab HES NCT00086658 - Eligibility Criteria Worksheet Screening Visit

- 04/06/2017 - 1 Formulaire, 2 Groupes Item, 12 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study part: Eligibility Criteria Worksheet Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial